Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID BRAY

Allopathic & Osteopathic Physicians Dermatology

NPI
1740266386
CMS profile
260310
Location
ALEXANDRIA, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$18,166.87

144 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID BRAY

NPI 1740266386 · CMS profile ID 260310

Allopathic & Osteopathic Physicians / Dermatology

ALEXANDRIA, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740266386?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID BRAY, NPI 1740266386, CMS profile ID 260310. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740266386?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DAVID BRAY, NPI 1740266386, CMS profile ID 260310. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740266386?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DAVID BRAY, NPI 1740266386, CMS profile ID 260310, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1740266386?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

144 matching records · $18,166.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 144 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–144 of 144.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Almirall LLC $10.9403/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676649175 CMS
Celgene Corporation $24.0803/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672838019 CMS
Mayne Pharma Inc. $19.5803/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705490069 CMS
Galderma Laboratories, L.P. $16.5503/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687666389 CMS
Sandoz Inc. $17.2503/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 639783815 CMS
Galderma Laboratories, L.P. $122.9203/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687666385 CMS
Galderma Laboratories, L.P. $47.1403/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687666387 CMS
Celgene Corporation $6.1303/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672749196 CMS
Janssen Biotech, Inc. $15.2503/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658343589 CMS
Galderma Laboratories, L.P. $12.3203/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687666383 CMS
Novartis Pharmaceuticals Corporation $15.1103/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658897233 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $18.9703/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684569595 CMS
TARO PHARMACEUTICALS USA, INC. $15.3903/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704148249 CMS
Galderma Laboratories, L.P. $2.9503/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687666381 CMS
Promius Pharma LLC $29.0003/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701094739 CMS
Sun Pharmaceutical Industries Inc. $20.0003/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704632943 CMS
Janssen Scientific Affairs, LLC $123.7503/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657589085 CMS
Galderma Laboratories, L.P. $99.5203/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687666379 CMS
Lilly USA, LLC $99.4503/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657783643 CMS
Novartis Pharmaceuticals Corporation $26.4403/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658897229 CMS
Galderma Laboratories, L.P. $135.0802/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687666377 CMS
PFIZER INC. $15.2602/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672418445 CMS
Janssen Biotech, Inc. $14.5602/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658343585 CMS
AbbVie, Inc. $120.2802/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648106647 CMS
Regeneron Healthcare Solutions, Inc. $10.9602/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673350036 CMS
Amgen Inc. $14.6702/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662294625 CMS
UCB, Inc. $123.7402/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688382039 CMS
Galderma Laboratories, L.P. $15.4302/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687666375 CMS
Celgene Corporation $5.9102/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672754857 CMS
AbbVie, Inc. $23.2702/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648106639 CMS
Janssen Biotech, Inc. $14.2402/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658343583 CMS
Lilly USA, LLC $21.3502/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657769635 CMS
Mayne Pharma Inc. $24.3201/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705490067 CMS
Celgene Corporation $22.1401/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672733467 CMS
Janssen Biotech, Inc. $14.6101/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658343579 CMS
PruGen, Inc. Pharmaceuticals $0.4901/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707765809 CMS
PruGen, Inc. Pharmaceuticals $15.4601/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707765815 CMS
Mylan Pharmaceuticals Inc. $13.0701/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694803167 CMS
AbbVie, Inc. $21.5001/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648106635 CMS
Galderma Laboratories, L.P. $19.5901/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687666373 CMS
Sun Pharmaceutical Industries Inc. $17.9301/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704632941 CMS
Janssen Biotech, Inc. $2.8101/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658343575 CMS
UCB, Inc. $13.6401/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688253587 CMS
UCB, Inc. $1.4301/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688352297 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $18,166.87 144
PY2020 $3,729.90 73
PY2021 $7,859.12 109
PY2022 $12,799.37 117
PY2023 $19,277.72 142
PY2024 $29,426.89 144
PY2025 $24,860.07 137

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $444,168.11 53
PY2024 Recipient $1,921.15 12
PY2024 Principal investigator $145,177.17 13
PY2023 Recipient $9,000.00 1
PY2023 Principal investigator $2,758.80 1
PY2022 Principal investigator $23,214.80 4
PY2021 Principal investigator $61,290.40 1
PY2020 Principal investigator $6,400.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $4,191.00 12/22/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226112786
Principal investigator 1 SANOFI US SERVICES INC. $8,232.00 12/15/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112811
Principal investigator 1 SANOFI US SERVICES INC. $195.00 12/08/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112741
Principal investigator 1 SANOFI US SERVICES INC. $210.00 12/08/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226112767
Principal investigator 1 SANOFI US SERVICES INC. $23,700.00 12/08/2025 Non-covered Recipient Entity
Care Access Research Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226112781
Principal investigator 1 SANOFI US SERVICES INC. $9,435.00 11/17/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226112699
Principal investigator 1 SANOFI US SERVICES INC. $4,926.00 11/17/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112737
Principal investigator 1 Novartis Pharmaceuticals Corporation $59,968.51 11/10/2025 Non-covered Recipient Entity
CARE ACCESS ALEXANDRIA
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190312891
Principal investigator 1 SANOFI US SERVICES INC. $8,463.00 11/10/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112723
Principal investigator 1 SANOFI US SERVICES INC. $750.00 11/04/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226112714
Principal investigator 1 SANOFI US SERVICES INC. $2,250.00 10/27/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112681
Principal investigator 1 SANOFI US SERVICES INC. $750.00 10/20/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112638
Principal investigator 1 SANOFI US SERVICES INC. $2,139.60 10/06/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112622
Principal investigator 1 SANOFI US SERVICES INC. $4,968.00 09/08/2025 Non-covered Recipient Entity
University Clinical Research Deland Accel Research Sites
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226093680
Principal investigator 1 Incyte Corporation $2,690.00 09/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240512944
Principal investigator 1 Incyte Corporation $750.00 09/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240512948
Principal investigator 1 Incyte Corporation $1,500.00 09/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240512952
Principal investigator 1 Incyte Corporation $1,000.00 09/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240512957
Principal investigator 1 Incyte Corporation $15,000.00 09/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240512961
Principal investigator 1 Incyte Corporation $1,750.00 09/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240512966
Principal investigator 1 SANOFI US SERVICES INC. $515.00 08/25/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112571
Principal investigator 1 SANOFI US SERVICES INC. $29,235.00 08/18/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112533
Principal investigator 1 SANOFI US SERVICES INC. $62.90 07/14/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112413
Principal investigator 1 SANOFI US SERVICES INC. $275.00 07/14/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112419
Principal investigator 1 SANOFI US SERVICES INC. $470.00 07/07/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112335
Principal investigator 1 SANOFI US SERVICES INC. $85.00 07/07/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112341
Principal investigator 1 SANOFI US SERVICES INC. $4,500.00 07/07/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113394
Principal investigator 1 SANOFI US SERVICES INC. $664.90 07/02/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112437
Principal investigator 1 SANOFI US SERVICES INC. $5,809.00 07/02/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112473
Principal investigator 1 SANOFI US SERVICES INC. $425.00 07/02/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112479
Principal investigator 1 Genentech, Inc. $2,501.00 06/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583716
Principal investigator 1 Genentech, Inc. $1,501.00 06/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583725
Principal investigator 1 Genentech, Inc. $1,750.00 06/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583730
Principal investigator 1 Genentech, Inc. $16,501.00 06/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583741
Principal investigator 1 Genentech, Inc. $1,001.00 06/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583749
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 06/09/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113325
Principal investigator 1 SANOFI US SERVICES INC. $17,930.50 05/12/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113271
Principal investigator 1 SANOFI US SERVICES INC. $7,920.13 05/05/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113232
Principal investigator 1 SANOFI US SERVICES INC. $9,344.50 04/28/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113196
Principal investigator 1 SANOFI US SERVICES INC. $2,250.00 04/28/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113237
Principal investigator 1 SANOFI US SERVICES INC. $9,285.00 04/14/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113176
Principal investigator 1 Eli Lilly and Company $4,667.07 03/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187878969
Principal investigator 1 SANOFI US SERVICES INC. $7,997.00 03/24/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113056
Principal investigator 1 SANOFI US SERVICES INC. $10,548.00 03/17/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112934
Principal investigator 1 SANOFI US SERVICES INC. $540.00 03/17/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112944
Principal investigator 1 SANOFI US SERVICES INC. $23,700.00 03/04/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226113018
Principal investigator 1 SANOFI US SERVICES INC. $705.00 02/18/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112874
Principal investigator 1 SANOFI US SERVICES INC. $375.00 02/18/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112887
Principal investigator 1 SANOFI US SERVICES INC. $375.00 02/18/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112950
Principal investigator 1 SANOFI US SERVICES INC. $12,890.00 02/10/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113014
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,300.00 01/21/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190311137
Principal investigator 1 SANOFI US SERVICES INC. $8,418.00 01/21/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112905
Principal investigator 1 Eli Lilly and Company $84,759.00 01/13/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187877209